GB0005703D0 - Compounds - Google Patents

Compounds

Info

Publication number
GB0005703D0
GB0005703D0 GBGB0005703.4A GB0005703A GB0005703D0 GB 0005703 D0 GB0005703 D0 GB 0005703D0 GB 0005703 A GB0005703 A GB 0005703A GB 0005703 D0 GB0005703 D0 GB 0005703D0
Authority
GB
United Kingdom
Prior art keywords
hydrogen atoms
group
lipophilic
amino acids
cationic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0005703.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xellia Pharmaceuticals AS
Original Assignee
Alpharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpharma AS filed Critical Alpharma AS
Priority to GBGB0005703.4A priority Critical patent/GB0005703D0/en
Publication of GB0005703D0 publication Critical patent/GB0005703D0/en
Priority to AT01910034T priority patent/ATE528017T1/de
Priority to EP10011411A priority patent/EP2338522A1/en
Priority to AU3761601A priority patent/AU3761601A/xx
Priority to US10/221,040 priority patent/US7232803B2/en
Priority to JP2001564799A priority patent/JP2004514644A/ja
Priority to PCT/GB2001/001035 priority patent/WO2001066147A2/en
Priority to AU2001237616A priority patent/AU2001237616B2/en
Priority to CA2400410A priority patent/CA2400410C/en
Priority to EP01910034A priority patent/EP1263471B1/en
Priority to DK01910034.6T priority patent/DK1263471T3/da
Priority to NO20024218A priority patent/NO334230B1/no
Priority to US11/738,098 priority patent/US8048852B2/en
Priority to US13/239,662 priority patent/US9115169B2/en
Priority to JP2012158714A priority patent/JP5554810B2/ja
Priority to JP2014081982A priority patent/JP5747100B2/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0005703.4A 2000-03-09 2000-03-09 Compounds Ceased GB0005703D0 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
GBGB0005703.4A GB0005703D0 (en) 2000-03-09 2000-03-09 Compounds
DK01910034.6T DK1263471T3 (da) 2000-03-09 2001-03-09 Antimikrobielle forbindelser og formuleringer
PCT/GB2001/001035 WO2001066147A2 (en) 2000-03-09 2001-03-09 Antimicrobial compounds and formulations
CA2400410A CA2400410C (en) 2000-03-09 2001-03-09 Antimicrobial compounds and formulations
AU3761601A AU3761601A (en) 2000-03-09 2001-03-09 Antimicrobial compounds and formulations
US10/221,040 US7232803B2 (en) 2000-03-09 2001-03-09 Antimicrobial compounds and formulations
JP2001564799A JP2004514644A (ja) 2000-03-09 2001-03-09 抗菌化合物および処方物
AT01910034T ATE528017T1 (de) 2000-03-09 2001-03-09 Antimikrobiellen verbindungen und formulierungen
AU2001237616A AU2001237616B2 (en) 2000-03-09 2001-03-09 Antimicrobial compounds and formulations
EP10011411A EP2338522A1 (en) 2000-03-09 2001-03-09 Antitumoural therapies
EP01910034A EP1263471B1 (en) 2000-03-09 2001-03-09 Antimicrobial compounds and formulations
NO20024218A NO334230B1 (no) 2000-03-09 2002-09-04 Peptid eller peptidmimetukum og anvendelse derav
US11/738,098 US8048852B2 (en) 2000-03-09 2007-04-20 Antimicrobial compounds and formulations
US13/239,662 US9115169B2 (en) 2000-03-09 2011-09-22 Method of treating tumors
JP2012158714A JP5554810B2 (ja) 2000-03-09 2012-07-17 抗菌化合物および処方物
JP2014081982A JP5747100B2 (ja) 2000-03-09 2014-04-11 抗菌化合物および処方物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0005703.4A GB0005703D0 (en) 2000-03-09 2000-03-09 Compounds

Publications (1)

Publication Number Publication Date
GB0005703D0 true GB0005703D0 (en) 2000-05-03

Family

ID=9887297

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0005703.4A Ceased GB0005703D0 (en) 2000-03-09 2000-03-09 Compounds

Country Status (10)

Country Link
US (3) US7232803B2 (https=)
EP (2) EP1263471B1 (https=)
JP (3) JP2004514644A (https=)
AT (1) ATE528017T1 (https=)
AU (2) AU2001237616B2 (https=)
CA (1) CA2400410C (https=)
DK (1) DK1263471T3 (https=)
GB (1) GB0005703D0 (https=)
NO (1) NO334230B1 (https=)
WO (1) WO2001066147A2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8283315B2 (en) 1998-08-28 2012-10-09 Lytix Biopharma As Inhibition of tumour growth
GB0005703D0 (en) 2000-03-09 2000-05-03 Alpharma As Compounds
AU2001270098A1 (en) * 2000-06-22 2002-01-02 San Diego State University Foundation Recombination modulators and methods for their production and use
NO20031818D0 (no) * 2003-04-23 2003-04-23 Uni I Tromsoe Fremgangsmåte av bioaktiv peptid forberedelse
JP4879020B2 (ja) * 2003-05-01 2012-02-15 コーネル リサーチ ファウンデイション インコーポレイテッド 細胞に分子を送達する方法及び担体複合体
WO2005074968A2 (en) * 2004-02-10 2005-08-18 Universiteit Maastricht Medical use of basic peptides
WO2007127457A2 (en) * 2006-04-28 2007-11-08 The Administrators Of The Tulane Educational Fund Ghrelin/growth hormone releasing peptide/growth hormone secretatogue receptor antagonists and uses thereof
US7960339B2 (en) * 2006-07-10 2011-06-14 Österreichische Akademie der Wissenschaften Antimicrobial peptides
GB0724951D0 (en) 2007-12-20 2008-01-30 Lytix Biopharma As Compounds
GB0724953D0 (en) 2007-12-20 2008-01-30 Lytix Biopharma As Methods of peptide modification
US9139355B2 (en) * 2008-04-18 2015-09-22 Medline Industries, Inc. Glove packaging having antimicrobial barrier
US9409946B2 (en) 2008-06-17 2016-08-09 Peptisyntha Peptide manufacturing process
GB0818074D0 (en) * 2008-10-02 2008-11-05 Lytix Biopharma As Treatment of biofilms
GB0821616D0 (en) 2008-11-26 2008-12-31 Lytix Biopharma As Compounds
US9724381B2 (en) 2009-05-12 2017-08-08 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
WO2011009903A2 (de) * 2009-07-21 2011-01-27 Udo Bogner Endoperoxidhaltiges materialsystem mit anpassung des zerfalls und anwendungen
US9550811B2 (en) 2010-12-02 2017-01-24 Bionor Immuno As Peptide scaffold design
US9493514B2 (en) 2011-01-06 2016-11-15 Bionor Immuno As Dimeric scaffold proteins comprising HIV-1 GP120 and GP41 epitopes
WO2012154959A1 (en) * 2011-05-11 2012-11-15 Elixir Institute Of Regenerative Medicine Peptide tyrosinase inhibitors and uses thereof
US20150018311A1 (en) * 2012-01-09 2015-01-15 University of Tromsø Therapeutic boron-containing compounds
CN104363756B (zh) * 2012-04-18 2017-10-31 农村振兴厅 含有二肽衍生物作为活性成分的农业植物‑保护剂
JP6310909B2 (ja) 2012-06-06 2018-04-11 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ 免疫原及び投薬反応物として使用するためのウイルスタンパク質に由来するペプチド
TWI577697B (zh) * 2013-11-28 2017-04-11 國立清華大學 耐高鹽及抗蛋白之抗菌胜肽及其製造方法
EP3071591B1 (en) * 2014-01-22 2021-05-05 Agency For Science, Technology And Research Antimicrobial peptidomimetics
EP3497965B1 (en) 2016-08-11 2022-04-13 Kyocera Corporation Ran-assisted rate adaptation
WO2018160791A1 (en) 2017-03-03 2018-09-07 Massachusetts Institute Of Technology Antimicrobial constructs and uses thereof
CN110938112A (zh) * 2019-12-10 2020-03-31 倪京满 脂肪酸修饰的超短序列抗菌肽类似物及其应用
CN110950932B (zh) * 2020-01-09 2023-04-18 福州大学 一种修饰肽的制备及其应用
US20230109142A1 (en) 2020-02-14 2023-04-06 Immunor As Corona virus vaccine
CN113248572B (zh) * 2021-04-30 2023-04-11 重庆理工大学 一种抗多重耐药菌环肽及其应用
CN120476131A (zh) * 2023-01-05 2025-08-12 埃米考特公司 涉及位阻三叔丁基色氨酸（Tbt）残基的肽合成方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668254A (en) * 1990-05-11 1997-09-16 Romano Deghenghi D-2-alkyl-tryptophan and peptides containing same
JP3009718B2 (ja) * 1990-10-01 2000-02-14 日本合成化学工業株式会社 新規ペプチド、その製造法及び用途
JP2771068B2 (ja) * 1991-03-13 1998-07-02 森永乳業株式会社 抗菌性ペプチドおよび抗菌剤
NZ241936A (en) * 1991-03-13 1994-03-25 Morinaga Milk Industry Co Ltd Antimicrobial peptide and its use in an antimicrobial composition
DK0510912T3 (da) * 1991-04-24 1998-02-09 Morinaga Milk Industry Co Ltd Antimikrobielt peptid og antimikrobielt middel
JP3173857B2 (ja) * 1991-04-24 2001-06-04 森永乳業株式会社 抗菌性ペプチドおよび抗菌剤
JP3173858B2 (ja) * 1991-04-24 2001-06-04 森永乳業株式会社 抗菌性ペプチドおよび抗菌剤
US5547939A (en) * 1991-06-14 1996-08-20 The Regents Of The University Of California Broad spectrum antimicrobial compounds and methods of use
US5885782A (en) * 1994-09-13 1999-03-23 Nce Pharmaceuticals, Inc. Synthetic antibiotics
WO1997000889A1 (en) * 1995-06-21 1997-01-09 Asahi Kasei Kogyo Kabushiki Kaisha Peptides binding to low-density lipoproteins
IL117223A0 (en) 1996-02-22 1996-06-18 Yeda Res & Dev Antipathogenic polypeptides and compositions comprising them
IL118003A0 (en) * 1996-04-23 1996-08-04 Yeda Res & Dev Novel vip fragments and pharmaceutical compositions comprising them
US5948889A (en) 1996-05-21 1999-09-07 Case Western Reserve University Compositions and methods for screening antimicrobials
DE19818802A1 (de) * 1998-04-27 1999-10-28 Dresden Arzneimittel Stabile Mitoxantron-Lösungen
PL344049A1 (en) * 1998-05-18 2001-09-24 Upjohn Co Enhancement of oxazolidinone antibacterial agents activity by using arginine derivatives
GB9818938D0 (en) * 1998-08-28 1998-10-21 Alpharma As Bioactive peptides
GB0005702D0 (en) 2000-03-09 2000-05-03 Alpharma As Method
GB0005703D0 (en) * 2000-03-09 2000-05-03 Alpharma As Compounds
US20030059827A1 (en) * 2001-03-13 2003-03-27 Cayetano Gonzalez Engineered protein binding domains and methods and systems for their design and use
US7291698B2 (en) * 2001-09-04 2007-11-06 Stephen Eliot Zweig Synthetic substrate for high specificity enzymatic assays

Also Published As

Publication number Publication date
ATE528017T1 (de) 2011-10-15
DK1263471T3 (da) 2012-02-06
JP5747100B2 (ja) 2015-07-08
JP2014196302A (ja) 2014-10-16
AU3761601A (en) 2001-09-17
JP5554810B2 (ja) 2014-07-23
NO20024218L (no) 2002-11-05
JP2004514644A (ja) 2004-05-20
NO20024218D0 (no) 2002-09-04
EP1263471A2 (en) 2002-12-11
JP2012229254A (ja) 2012-11-22
CA2400410C (en) 2013-06-11
WO2001066147A3 (en) 2002-04-11
US20120108520A1 (en) 2012-05-03
WO2001066147A2 (en) 2001-09-13
AU2001237616B2 (en) 2005-08-11
EP1263471B1 (en) 2011-10-12
US9115169B2 (en) 2015-08-25
US7232803B2 (en) 2007-06-19
US20030195144A1 (en) 2003-10-16
US8048852B2 (en) 2011-11-01
US20100267621A1 (en) 2010-10-21
EP2338522A1 (en) 2011-06-29
NO334230B1 (no) 2014-01-13
CA2400410A1 (en) 2001-09-13

Similar Documents

Publication Publication Date Title
GB0005703D0 (en) Compounds
ATE263157T1 (de) Nematizide trifluorbutene
ZA975443B (en) Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides.
GR3034924T3 (en) Novel peptide derivatives
DK0696270T3 (da) 4-Aminofluorbenzamider og deres anvendelse som cytotoksiske promedikamenter
BR9909844A (pt) Processo para sintetizar um composto, e, composto.
IL136044A (en) 2-aminoacetamide derivatives and pharmaceutical compositions containing the same
BRPI0115953B8 (pt) complexos de derivados de fosfato
KR970704864A (ko) 세정제 조성물
SE8702550D0 (sv) Cysteinproteashemmare
IN2012DE00109A (https=)
NZ320580A (en) Tricyclic compounds, preparation and pharmaceutical compositions thereof
ES2155460T3 (es) Sintesis en fase solida de oligorribonucleotidos.
NO20002548D0 (no) Nye substituerte dimere forbindelser, en fremgangsmÕte ved deres fremstilling og farmasøytiske sammensetninger som inneholder dem
FR2818906B1 (fr) Association medicamenteuse d'une biguanine et d'un transporteur, par exemple de metformine et d'arginine
BR9808447A (pt) Composto, uso do mesmo, processo para sua preparação, e, composição farmacêutica
BR9807785A (pt) Processo para a preparação do composto, e, composto
MX9603568A (es) Derivados de la alquenil-benzoilguanidina.
EP1295874A3 (en) Retroviral protease inhibiting compounds
DE69600566D1 (de) Vorbereitung von geschützten Aminen bzw. alkylierten Aminosäuren
BR0317702A (pt) Processo de sìntese da 3,3a,6,6a-tetrahidro-2h-ciclopentan[b]furan-2-ona
ZA991571B (en) GLP-1 derivatives II.
CA2234611A1 (en) New phenylamidine derivatives, processes for preparing them and their use as pharmaceutical compositions

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)